Obesity, obstructive sleep apnoea and metabolic syndrome

Respirology

Volumn 17, Issue 2, 2012, Pages 223-236

  Lam, Jamie Chung Mei ^a   Mak, Judith Choi Wo ^a   Ip, Mary Sau Man ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

mechanistic pathway; metabolic syndrome; obesity; obstructive sleep apnoea

Indexed keywords

ADIPONECTIN; CYTOKINE; FATTY ACID BINDING PROTEIN 4; LEPTIN;

BODY MASS; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; HUMAN; HYPOXIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SLEEP APNEA SYNDROME; WEIGHT REDUCTION;

DEVELOPED COUNTRIES; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS; PREVALENCE; PUBLIC HEALTH; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE;

EID: 84856240103     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02081.x     Document Type: Review

References (156)

1. CDC. State-specific prevalence of obesity among adults - United States. MMWR Morb. Mortal. Wkly. Rep. 2005; 55: 985-8.
2. Poirier P, Giles TD, Bray GA, et al,. Obesity and cardiovascular disease - Pathophysiology, evaluation, and effect of weight loss. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 968-76. (Pubitemid 43732100)
3. Prospective Studies Collaboration. Body mass index and cause specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-96.
4. Coughlin S, Mawdsley L, Mugarza JA, et al,. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur. Heart J. 2004; 25: 735-41. (Pubitemid 38647933)
5. Lam JCM, Lam B, Lam CL, et al,. Obstructive sleep apnea and the metabolic syndrome in community-based Chinese subjects in Hong Kong. Respir. Med. 2006; 100: 980-87.
6. Young T, Palta M, Dempsey J, et al,. The occurrence of sleep-disordered breathing among middle-aged adults. N. Engl. J. Med. 1993; 328: 230-35.
7. Young T, Shahar E, Nieto F, et al,. Predictors of sleep-disordered breathing in community dwelling adults: the Sleep Heart Health Study. Arch. Intern. Med. 2002; 162: 893-900. (Pubitemid 34299121)
8. Pack AI, Pien GW,. Update on sleep and its disorders. Annu. Rev. Med. 2011; 62: 447-60.
9. Williams G, Fruhbeck G, (eds). Obesity: Science and Practice. Wiley, Oxford, 2009.
10. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Resp Ser 2000; 894: i-xii, 1-253.
11. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-63.
12. Grassi G, Seravalle G, Del'Orro R,. Sympathetic activation in obesity: a noninnocent bystander. Hypertension 2010; 56: 338-40.
13. Carey VJ, Walters EE, Colditz GA, et al,. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women: the nurses' health study. Am. J. Epidemiol. 1997; 145: 614-19. (Pubitemid 27154864)
14. Reaven G,. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607. (Pubitemid 19004941)
15. Lakka HM, Laaksonen DE, Lakka TA, et al,. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16. (Pubitemid 35403784)
16. Hanson RL, Imperatore G, Bennett PH, et al,. Components of the 'metabolic syndrome' and incidence of type 2 diabetes. Diabetes 2002; 51: 3120-27.
17. Laaksonen DE, Lakka HM, Niskanen LK, et al,. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am. J. Epidemiol. 2002; 156: 1070-77. (Pubitemid 35396938)
18. Simons LA, Simons J, Friedlander Y, et al,. Is prediction of cardiovascular disease and all-cause mortality genuinely driven by the metabolic syndrome, and independently from its component variables? The Dubbo study. Heart Lung Circ. 2011; 20: 214-19.
19. Eckel RH, Grundy SM,. The metabolic syndrome. Lancet 2005; 365: 1415-28. (Pubitemid 40523737)
20. Lam JC, Ip MS,. Sleep and the metabolic syndrome. Indian J. Med. Res. 2010; 131: 206-16.
21. Cameron AJ, Shaw JE, Zimmet PZ,. The metabolic syndrome: prevalence in worldwide populations. Endocrinol. Metab. Clin. North Am. 2004; 33: 351-75. (Pubitemid 38680634)
22. Weiss R, Dziura J, Burgert TS, et al,. Obesity and the metabolic syndrome in children and adolescent. N. Engl. J. Med. 2004; 350: 2362-74. (Pubitemid 38702847)
23. Grundy SM, Cleeman JI, Daniels RD, et al,. Diagnosis and management of the metabolic syndrome - an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52. (Pubitemid 41532612)
24. Jensen MD,. Is visceral fat involved in the pathogenesis of the metabolic syndrome? Human model. Obesity 2006; 14: S20-24.
25. Kissebath AH,. Central obesity: measurement and metabolic effects. Diabet. Rev. 1997; 5: 8-20.
26. Bergman RN, Kim SP, Catalano KJ, et al,. Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity 2006; 14: S16-19.
27. Schwartz AR, Patil SP, Laffan AM, et al,. Obesity and obstructive sleep apnea - pathogenic mechanisms and therapeutic approaches. Proc. Am. Thorac. Soc. 2008; 5: 185-92. (Pubitemid 351237877)
28. Peppard PE, Young T, Palta M, et al,. Longitudinal study of moderate weight change of sleep-disordered breathing. JAMA 2000; 284: 3015-21. (Pubitemid 32014738)
29. Newman AB, Foster G, Givelber R, et al,. Progression and regression of sleep-disordered breathing with changes in weight: the Sleep Heart Health Study. Arch. Intern. Med. 2005; 165: 2408-13. (Pubitemid 41640854)
30. Phillips BG, Hisel TM, Kato M, et al,. Recent weight gain in patients with newly diagnosed obstructive sleep apnea. J. Hypertens. 1999; 17: 1297-300. (Pubitemid 29509508)
31. Phillips BG, Kato M, Narkiewicz K, et al,. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am. J. Physiol. Heart Circ. Physiol. 2000; 279: H234-7. (Pubitemid 30616665)
32. Onat A, Hergenc G, Yuksel H, et al,. Neck circumference as a measure of central obesity: associations with metabolic syndrome and obstructive sleep apnea beyond waist circumference. Clin. Nutr. 2009; 28: 46-51.
33. Sharma SK, Kurian S, Malik V, et al,. A stepped approach for prediction of obstructive sleep apnea in overtly asymptomatic obese subjects: a hospital based study. Sleep Med. 2004; 5: 351-7. (Pubitemid 38842732)
34. Kawaguchi Y, Fukumoto S, Inaba M, et al,. Different impacts of neck circumference and visceral obesity on the severity of obstructive sleep apnea syndrome. Obesity 2011; 19: 276-82.
35. Lee RW, Vasudavan S, Hui DS, et al,. Differences in craniofacial structures and obesity in Caucasian and Chinese patients with obstructive sleep apnea. Sleep 2010; 33: 1075-80.
36. McClendon DA, Dunbar SB, Clark PC, et al,. An analysis of popular weight loss diet types in relation to metabolic syndrome therapeutic guidelines. Review. Medsurg Nurs. 2010; 19: 17-24.
37. Haines KL, Nelson LG, Gonzalez R, et al,. Objective evidence that bariatric surgery improves obesity-related obstructive sleep apnea. Surgery 2007; 141: 354-8. (Pubitemid 46356437)
38. Yee BJ, Phillips CL, Banerjee D, et al,. The effect of Sibutramine-assisted weight loss in men with obstructive sleep apnoea. Int. J. Obes. 2007; 31: 161-8. (Pubitemid 46006030)
39. Sutherland K, Lee RW, Phillips CL, et al,. Effect of weight loss on upper airway size and facial fat in men with obstructive sleep apnoea. Thorax 2011; 66: 797-803.
40. Grunstein RR, Stenlof K, Hedner JA, et al,. Two year reduction in sleep apnea syndromes and associated diabetes incidence after weight loss in severe obesity. Sleep 2007; 30: 703-10. (Pubitemid 46854757)
41. Phillips CL, Yee BJ, Trenell MI, et al,. Changes in regional adiposity and cardiometabolic function following a weight loss program with Sibutramine in obese men with obstructive sleep apnea. J. Clin. Sleep Med. 2009; 5: 416-21.
42. Dixon JB, Schachter LM, O'Brien PE,. Polysomnography before and after weight loss in obese patients with severe sleep apnea. Int. J. Obes. (Lond) 2005; 29: 1048-54. (Pubitemid 41192211)
43. Vgontzas AN,. Does obesity play a major role in the pathogenesis of sleep apnoea and its associated manifestations via inflammation, visceral adiposity, and insulin resistance? Arch. Physiol. Biochem. 2008; 114: 211-23.
44. Rosmond R, Dallman MF, Bjorntorp P,. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J. Clin. Endocrinol. Metab. 1998; 83: 1853-9. (Pubitemid 28496305)
45. Grunstein RR, Wilcox I, Yang TS, et al,. Snoring and sleep apnea in men: association with central obesity and hypertension. Int. J. Obes. Relat. Metab. Disord. 1993; 17: 533-40. (Pubitemid 23269132)
46. Tasali E, Van Cauter E,. Sleep disordered breathing and the current epidemic of obesity - consequence or contributing factor? The editorials. Am. J. Respir. Crit. Care Med. 2002; 165: 562-3. (Pubitemid 34194746)
47. Vgontzas AN, Bixler EO, Chrousos GP,. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med. Rev. 2005; 9: 211-24. (Pubitemid 40694188)
48. Fantuzzi G,. Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol. 2005; 115: 911-19.
49. Trayhurn P, Wang B, Wood IS,. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br. J. Nutr. 2008; 100: 227-35.
50. Hotamisligil GS,. Inflammation and metabolic disorders. Nature 2004; 444: 860-7. (Pubitemid 46024993)
51. Berg AH, Scherer PE,. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 2005; 96: 939-49. (Pubitemid 40712793)
52. Lavie L,. Obstructive sleep apnea syndrome-an oxidative stress disorder. Sleep Med. Rev. 2003; 7: 33-51.
53. Dixon JB, Bhathal PS, O'Brien PE,. Nonalcoholic fatty liver disease: predictors of non- alcoholic steatohepatitis and liver fibrosis in severely obese. Gastroenterology 2001; 121: 91-100. (Pubitemid 32591518)
54. Browning JD, Horton JD,. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 2004; 114: 147-52. (Pubitemid 39071617)
55. Norman D, Bardwell WA, Arosemena F, et al,. Serum aminotransferase levels are associated with markers of hypoxia in patients with obstructive sleep apnea. Sleep 2008; 31: 121-6.
56. Gruber A, Horwood F, Sithole J, et al,. Obstructive sleep apnoea is independently associated with metabolic syndrome but not the insulin resistance state. Cardiovasc. Diabetol. 2006; 5: 22 (1-7).
57. Parish JM, Adam T, Facchiano L,. Relationship of metabolic syndrome and obstructive sleep apnea. J. Clin. Sleep Med. 2007; 3: 467-72. (Pubitemid 47378249)
58. Nieto FJ, Peppard PF, Young TB,. Sleep disordered breathing and metabolic syndrome. WMJ 2009; 108: 263-5.
59. Oktay B, Akbal E, Firat H, et al,. CPAP treatment in the coexistence of obstructive sleep apnea syndrome and metabolic syndrome, results of one year follow up. Acta Clin. Belg. 2009; 64: 329-34.
60. Drager LF, Queiroz EL, Lopes HF, et al,. Obstructive sleep apnea is highly prevalent and correlates with impaired glycemic control in consecutive patients with the metabolic syndrome. J. Cardiometab. Syndr. 2009; 4: 89-95.
61. Trombetta IC, Somers VK, Maki-Nunes C, et al,. Consequences of comorbid sleep apnea in the metabolic syndrome - implications for cardiovascular risk. Sleep 2010; 33: 1193-9.
62. Ambrosetti M, Lucioni AM, Conti S, et al,. Metabolic syndrome in obstructive sleep apnea and related cardiovascular risk. J. Cardiovasc. Med. 2006; 7: 826-9. (Pubitemid 44632197)
63. Peled N, Kassirer M, Shitrit D, et al,. The association of OSA with insulin resistance, inflammation and metabolic syndrome. Respir. Med. 2007; 101: 1696-701. (Pubitemid 46947878)
64. Tkacova R, Dorkova Z, Molcanyiova A, et al,. Cardiovascular risk and insulin resistance in patients with obstructive sleep apnea. Med. Sci. Monit. 2008; 14: CR438-44.
65. Papanas N, Steiropoulos P, Nena E, et al,. Predictors of obstructive sleep apnea in males with metabolic syndrome. Vasc. Health Risk Manag. 2010; 6: 281-6.
66. Barcelo A, Pierola J, de la Pena M, et al,. Free fatty acids and the metabolic syndrome in patients with obstructive sleep apnoea. Eur. Respir. J. 2011; 37: 1418-23.
67. Zito A, Steiropoulos P, Barcelo A, et al,. Obstructive sleep apnoea and metabolic syndrome in Mediterranean countries. Eur. Respir. J. 2011; 37: 717-19.
68. Gasa M, Salord N, Fortuna AM, et al,. Obstructive sleep apnoea and metabolic impairment in severe obesity. Eur. Respir. J. 2011; 38: 1089-97.
69. Sasanabe R, Banno K, Otake K, et al,. Metabolic syndrome in Japanese patients with obstructive sleep apnea syndrome. Hypertens. Res. 2006; 29: 315-22. (Pubitemid 43965112)
70. Shiina K, Tomiyama H, Takata Y, et al,. Concurrent presence of metabolic syndrome in obstructive sleep apnea syndrome exacerbates the cardiovascular risk. A sleep clinic cohort study. Hypertens. Res. 2006; 29: 433-41. (Pubitemid 44102811)
71. Akahoshi T, Uematsu A, Akashiba T, et al,. Obstructive sleep apnoea is associated with risk factors comprising the metabolic syndrome. Respirology 2010; 15: 1122-6.
72. Takama N, Kurabayashi M,. Relationship between metabolic syndrome and sleep-disordered breathing in patients with cardiovascular disease - metabolic syndrome as a strong factor of nocturnal desaturation. Intern Med 2008; 47: 709-15. (Pubitemid 351936218)
73. Wilcox I, McNamara SG, Collins FL, et al,. 'Syndrome Z': the interaction of sleep apnea, vascular risk factors and heart disease. Thorax 1998; 3 (Suppl.): S25-8.
74. Kono M, Tatsumi K, Saibara T, et al,. Obstructive sleep apnea syndrome is associated with some components of metabolic syndrome. Chest 2007; 131: 1387-92. (Pubitemid 46762343)
75. McArdle N, Hillman D, Beilin L, et al,. Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am. J. Respir. Crit. Care Med. 2007; 175: 190-95. (Pubitemid 46115091)
76. Sharma SK, Sreenivas V,. Are metabolic syndrome, obstructive sleep apnea, syndrome Z sequential? - a hypothesis. Indian J. Med. Res. 2010; 131: 455-8.
77. Drager LF, Bortolotto LA, Maki-Nunes C, et al,. The incremental role of obstructive sleep apnea on markers of atherosclerosis in patients with metabolic syndrome. Artherosclerosis 2010; 208: 490-95.
78. Mota PC, Drummond M, Winck JC, et al,. APAP impact on metabolic syndrome in obstructive sleep apnea patients. Sleep Breath. 2010; doi: 10.1007/S11325-010-0417-5.
79. Lavie L, Polotsky V,. Cardiovascular aspects in obstructive sleep apnea syndrome - molecular issues, hypoxia and cytokine profiles. Respiration 2009; 78: 361-70.
80. Dyugovskaya L, Lavie P, Lavie L,. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am. J. Respir. Crit. Care Med. 2002; 165: 934-9. (Pubitemid 34774660)
81. Barcelo A, Miralles C, Barbe F, et al,. Abnormal lipid peroxidation in patients with sleep apnoea. Eur. Respir. J. 2000; 16: 644-7.
82. Yamauchi M, Nakano H, Maekawa J, et al,. Oxidative stress in obstructive sleep apnea. Chest 2005; 127: 1674-9. (Pubitemid 46218794)
83. Carpagnano GE, Kharitonov SA, Resta O, et al,. 8-isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy. Chest 2003; 124: 1386-92. (Pubitemid 37290049)
84. Pialoux V, Hanly PJ, Foster GE, et al,. Effects of exposure to intermittent hypoxia on oxidative stress and acute hypoxic ventilatory response in humans. Am. J. Respir. Crit. Care Med. 2009; 180: 1002-9.
85. Yuan G, Nanduri J, Khan S, et al,. Induction of HIF-1α expression by intermittent hypoxia: involvement of NADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR. J. Cell. Physiol. 2008; 217: 674-85.
86. Bedard K, Krause KH,. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 2007; 87: 245-313. (Pubitemid 46209993)
87. Lavie L,. Oxidative stress - a unifying paradigm in obstructive sleep apnea and comorbidities. Prog. Cardiovasc. Dis. 2009; 51: 303-12.
88. Muraki I, Tanigawa T, Yamagishi K, et al,. Nocturnal intermittent hypoxia and the development of type 2 diabetes: the Circulatory Risk in Communities Study (CIRCS). Diabetologia 2010; 53: 481-8.
89. Sulit L, Storfer-isser A, Kirchner HL, et al,. Differences in polysomnography predictors for hypertension and impaired glucose tolerance. Sleep 2006; 29: 777-83. (Pubitemid 43895046)
90. Resnick HE, Redline S, Shahar E, et al,. Sleep Heart Health Study. Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. Diabetes Care 2003; 26: 702-9. (Pubitemid 36929331)
91. Reichmuth KJ, Austin D, Skatrud B, et al,. Association of sleep apnea and type II diabetes: a population-based study. Am. J. Respir. Crit. Care Med. 2005; 172: 1590-95. (Pubitemid 43076551)
92. Louis M, Punjabi NM,. Effects of acute intermittent hypoxia on glucose metabolism in awake healthy volunteers. J. Appl. Physiol. 2009; 106: 1538-44.
93. Polotsky VY, Li J, Punjabi NM, et al,. Intermittent hypoxia increases insulin resistance in genetically obese mice. J. Physiol. 2003; 552: 253-64. (Pubitemid 37265483)
94. Iiyori N, Alonso LC, Li J, et al,. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am. J. Respir. Crit. Care Med. 2007; 175: 851-7. (Pubitemid 46631798)
95. Yokoe T, Alonso LC, Romano LC, et al,. Intermittent hypoxia reverses the diurnal glucose rhythm and causes pancreatic beta-cell replication in mice. J. Physiol. 2008; 586: 899-911. (Pubitemid 351194126)
96. Bertuglia S, Reiter RJ,. Melatonin reduces microvascular damage and insulin resistance in hamsters due to chronic intermittent hypoxia. J. Pineal Res. 2009; 46: 307-13.
97. Xu J, Long YS, Gozal D, et al,. Beta-cell death and proliferation after intermittent hypoxia: role of oxidative stress. Free Radic. Biol. Med. 2009; 46: 783-90.
98. Rosa DP, Martinez D, Picada JN, et al,. Hepatic oxidative stress in an animal model of sleep apnea: effects of different duration of exposure. Comp. Hepatol. 2011; 10: 1.
99. Li J, Savransky V, Nanayakkara A, et al,. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia. J. Appl. Physiol. 2007; 102: 557-63. (Pubitemid 46220883)
100. Li J, Nanayakkara A, Jun J, et al,. Effect of deficiency in SREBP cleavage-activating protein on lipid metabolism during intermittent hypoxia. Physiol. Genomics 2007; 31: 273-80. (Pubitemid 350014405)
101. Arnaud C, Beguin PC, Lantuejoul S, et al,. The inflammatory pre-atherosclerotic remodeling induced by intermittent hypoxia is attenuated by RANTES/CCL5 inhibition. Am. J. Respir. Crit. Care Med. 2011; 184: 724-31.
102. Dematteis M, Julien C, Guillermet C, et al,. Intermittent hypoxia induces early functional cardiovascular remodeling in mice. Am. J. Respir. Crit. Care Med. 2008; 177: 227-35.
103. Savransky V, Nanayakkara A, Li J, et al,. Chronic intermittent hypoxia induces atherosclerosis. Am. J. Respir. Crit. Care Med. 2007; 175: 11290-97.
104. Leinum CJ, Dopp JM, Morgan BJ,. Sleep disordered breathing and obesity: pathophysiology, complications and treatment. Nutr. Clin. Pract. 2009; 24: 675-87.
105. Kent BD, Ryan S, McNicholas WT,. Obstructive sleep apnea and inflammation: relationship to cardiovascular co-morbidity. Respir. Physiol. Neurobiol. 2011; 178: 475-81.
106. Calvin AD, Albuquerque FN, Lopez-Jimenez F, et al,. Obstructive sleep apnea, inflammation, and the metabolic syndrome. Metab. Syndr. Relat. Disord. 2009; 7: 271-8.
107. Trakada G, Chrousos G, Pejovic S, et al,. Sleep apnea and its association with the stress system, inflammation, insulin resistance and visceral obesity. Sleep Med. Clin. 2007; 2: 251-61.
108. Reinke C, Bevans-Fonti S, Drager LF, et al,. Effects of different acute hypoxic regimens on tissue oxygen profiles and metabolic outcomes. J. Appl. Physiol. 2011; 111: 881-90.
109. Nacher M, Serrano-Mollar A, Farre R, et al,. Recurrent obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea. Respir. Physiol. Neurobiol. 2007; 155: 93-6. (Pubitemid 46049132)
110. Tam CS, Wong M, Tam K, et al,. The effect of acute intermittent hypercapnic hypoxia treatment on IL-6, TNF-alpha, and CRP levels in piglets. Sleep 2007; 30: 723-7. (Pubitemid 46854759)
111. Williams A, Scharf SM,. Obstructive sleep apnea, cardiovascular disease, and inflammation - is NFkappaB the key? Sleep Breath. 2007; 11: 69-76. (Pubitemid 46745858)
112. Htoo AK, Greenberg H, Tongia S, et al,. Activation of nuclear factor kappaB in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath. 2006; 10: 43-50. (Pubitemid 44193436)
113. Ryan S, Taylor CT, McNicholas WT,. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005; 112: 2660-67. (Pubitemid 41532603)
114. Greenberg H, Ye X, Wilson D, et al,. Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem. Biophys. Res. Commun. 2006; 343: 591-6.
115. Toffoli S, Roegiers A, Feron O, et al,. Intermittent hypoxia is an angiogenic inducer for endothelial cells: role of HIF-1. Angiogenesis 2009; 12: 47-67.
116. Libby P, Ridker P, Maseri A,. Inflammation and atheroslcerosis. Circulation 2005; 105: 1135-43.
117. Park K, Steffes M, Lee DH, et al,. Association of inflammation with worsening HOMA-insulin resistance. Diabetologia. 2009; 52: 2337-44.
118. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al,. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105: 2462-4. (Pubitemid 34568964)
119. Taheri S, Austin D, Lin L, et al,. Correlates of serum C-reactive protein (CRP) - no association with sleep duration for sleep disoredered breathing. Sleep 2007; 30: 991-6. (Pubitemid 47221899)
120. Lui MM, Lam JC, Mak HK, et al,. C-reactive protein is associated with obstructive sleep apnea independent of visceral obesity. Chest 2009; 135: 950-56.
121. Ishida K, Kato M, Kato Y, et al,. Appropriate use of nasal continuous positive airway pressure decreases elevated C-reactive protein in patients with obstructive sleep apnea. Chest 2009; 136: 125-9.
122. Kohler MM, Ayers L, Pepperell JCT, et al,. Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomized controlled trial. Thorax 2008; 64: 67-73.
123. Stefan N, Vozarova B, Funahashi T, et al,. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002; 51: 1884-8. (Pubitemid 34564302)
124. Wolf AM, Wolf D, Rumpold H, et al,. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1 RA in human leukocytes. Biochem. Biophys. Res. Commun. 2004; 323: 630-35. (Pubitemid 39221142)
125. Ouchi N, Kihara S, Arita Y, et al,. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-6. (Pubitemid 30005109)
126. Kumada M, Kihara S, Sumitsuji S, et al,. Association of hypoadiponectinemia with coronary artery disease in men. Arteriocler. Thromb. Vasc. Biol. 2003; 23: 85-9. (Pubitemid 36091630)
127. Pischon T, Girman CJ, Hotamisligil GS, et al,. Plasma adiponectin levels and risk of myocardial infarction in man. JAMA 2004; 291: 1730-37. (Pubitemid 38489895)
128. Makino S, Handa H, Suzukawa K, et al,. Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance. Clin. Endocrinol. (Oxf.) 2006; 64: 12-19.
129. Wolk R, Svatikova A, Nelson CA, et al,. Plasma levels of adiponectin, a novel adipocyte-derived hormone, in sleep apnea. Obes. Res. 2005; 13: 186-90.
130. Lam JC, Xu A, Tam S, et al,. Hypoadiponectinemia is related to the sympathetic activity and severity of obstructive sleep apnea. Sleep 2008; 31: 1721-7.
131. Fasshauer M, Klein J, Neumann S, et al,. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett. 2001; 507: 142-6. (Pubitemid 33001531)
132. Carneiro G, Togeiro SM, Ribeiro-Filho FF, et al,. Continuous positive airway pressure therapy improves hypoadiponectinemia in severe obese men with obstructive sleep apnea without changes in insulin resistance. Metab. Syndr. Relat. Disord. 2009; 7: 537-42.
133. de Lima AM, Franco CM, de Castro CMM, et al,. Effects of nasal continuous positive airway pressure treatment on oxidative stress and adiponectin levels in obese patients with obstructive sleep apnea. Respiration 2010; 79: 370-76.
134. West SD, Nicoll DJ, Wallace TM, et al,. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007; 62: 969-74. (Pubitemid 350084496)
135. Magalang UJ, Cruff JP, Rajappan R, et al,. Intermittent hypoxia suppresses adiponectin secretion by adipocytes. Exp. Clin. Endocrinol. Diabetes 2009; 117: 129-34.
136. Marik PE,. Leptin, obesity, and obstructive sleep apnea. Chest 2000; 118: 569-70.
137. Considine RV, Sinha MK, Heiman ML, et al,. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 1996; 334: 292-5. (Pubitemid 26033933)
138. Snyder EM, Carr RD, Deacon CF, et al,. Overnight hypoxic exposure and glucagon-like peptide-1 and leptin levels in humans. Appl. Physiol. Nutr. Metab. 2008; 33: 929-35.
139. Vgontzas AN, Papanicolaou DA, Bixler EO, et al,. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J. Clin. Endocrinol. Metab. 2000; 85: 1151-8. (Pubitemid 32269364)
140. Phillips BG, Kato M, Narkiewicz K, et al,. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am. J. Physiol. Heart Circ. Physiol. 2000; 279: H234-7. (Pubitemid 30616665)
141. Ip MS, Lam KSL, Ho CM, et al,. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest 2000; 118: 580-86.
142. Tokuda F, Sando Y, Matsui H, et al,. Serum levels of adipocytokines, adiponectin and leptin in patients with obstructive sleep apnea syndrome. Intern Med 2008; 47: 1843-9.
143. Ciftci TU, Kokturk O, Bukan N, et al,. Leptin and Ghrelin levels in patients with obstructive sleep apnea syndrome. Respiration 2005; 72: 395-401. (Pubitemid 41160173)
144. Shimizu K, Chin K, Nakamura T, et al,. Plasma leptin levels and cardiac sympathetic function in patients with obstructive sleep apnoea-hypopnoea syndrome. Thorax 2002; 57: 429-34. (Pubitemid 34494154)
145. Luo JD, Zhang GS, Chen MS,. Leptin and cardiovascular diseases. Drug News Perspect. 2005; 18: 427-31.
146. Parhami F, Tintut Y, Ballard A, et al,. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ. Res. 2001; 88: 954-60. (Pubitemid 32441475)
147. Chin K, Shimizu K, Nakamura T, et al,. Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation 1999; 100: 706-12. (Pubitemid 29383639)
148. Harsch IA, Konturek PC, Koebnick C, et al,. Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. Eur. Respir. J. 2003; 22: 251-7. (Pubitemid 36986993)
149. Makowski L, Brittingham KC, Reynolds JM, et al,. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome. J. Biol. Chem. 2005; 280: 12888-95.
150. Uysal KT, Scheja L, Wiesbrock SM, et al,. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 2000; 141: 3388-96. (Pubitemid 32269028)
151. Boord JB, Fazio S, Linton MF,. Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr. Opin. Lipidol. 2002; 13: 141-7. (Pubitemid 34280765)
152. Furuhashi M, Fucho R, Gorgun CZ, et al,. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J. Clin. Invest. 2008; 118: 2640-50. (Pubitemid 351949791)
153. Makowski L, Boord JB, Maeda K, et al,. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med. 2001; 7: 699-705. (Pubitemid 32588026)
154. Tuncman G, Erbay E, Hom X, et al,. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc. Natl. Acad. Sci. U S A 2006; 103: 6970-75.
155. Lam CL, Xu A, Lam KSL, et al,. Serum adipocyte-fatty acid binding protein level is elevated in severe OSA and correlates with insulin resistance. Eur. Respir. J. 2009; 33: 346-51.
156. Han Q, Yeung SC, Ip MS, et al,. Effects of intermittent hypoxia on A-/E-FABP expression in human aortic endothelial cells. Int. J. Cardiol. 2010; 145: 396-8.